The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of chronic kidney disease (CKD). This approval allows nephrologists and cardiologists to use Jardiance for eligible CKD patients, reducing hospitalizations and addressing unmet medical needs.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.